Today, we take you behind the scenes of something rare: a tour inside Incyte’s research labs in Wilmington, Delaware, followed by the Patient Advocacy Summit.

Day One (September 4, 2025) felt almost cinematic — community leaders walking the same halls as scientists, asking everything from “What does it take to become a scientist?” to “How do you decide which molecule deserves millions in investment?”

No staged press moments, just real dialogue about the alchemy of discovery, where 400,000 compounds can be narrowed down to one therapy like Opzelura.

Day Two (September 5, 2025) shifted to strategy and policy. Advocates sat across from Incyte’s executive team, pressing on real-world issues: access, safety, pediatric use, adherence, and what it means to be the first mover while competitors close in. The conversations spanned treatment motivation, behavioral economics, insurance battles, and even research linking vitiligo to industrial pollutants.

At the heart of it all was the human element — the faces behind the data, the advocates shaping the agenda, and the scientists listening and learning from lived experience.

The big takeaway? Progress in vitiligo happens when patients and researchers sit at the same table — not as bystanders, but as true partners.

Dig deeper for more details:

• A Rare Look Inside Incyte's Labs. Day One
• Patient Advocacy Summit Report. Day Two